The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N03 | Antiepileptics | |
| 3 | N03A | Antiepileptics | |
| 4 | N03AX | Other antiepileptics | |
| 5 | N03AX14 | Levetiracetam |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 1.5 g |
| PAREN - Parenteral | 1.5 g |
| Active Ingredient | Description | |
|---|---|---|
| Levetiracetam |
Levetiracetam, is a pyrrolidone derivative, chemically unrelated to existing antiepileptic active substances. Levetiracetam induces seizure protection in a broad range of animal models of partial and primary generalised seizures without having a pro-convulsant effect. The primary metabolite is inactive. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| KEPPRA Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| KEPPRA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| LEVECETAM Film-coated tablet | Pharmaceutical Benefits Scheme (AU) | MPI, EU: SmPC | |
| QUETRA Film-coated tablet | Medicines Authority (MT) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
